CD163 and colorectal carcinoma: Yang et al.234 evaluated TAM markers (CD68 and CD163) in 81 CRC patients via immunohistochemistry and compared the survival rates of patients with high CD163+/CD68+ ratios with those of patients with low CD163+/CD68+ ratios.